These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19816443)

  • 41. Something more is necessary: are genes and genetic diagnostic tests statutory subject matter for US patents?
    Cockbain J; Sterckx S
    Expert Rev Mol Diagn; 2011 Mar; 11(2):149-58. PubMed ID: 21405966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of genetic tests unnecessary, government says.
    Webster PC
    CMAJ; 2010 Nov; 182(16):1715-6. PubMed ID: 20921255
    [No Abstract]   [Full Text] [Related]  

  • 43. Intellectual property. Patents on human genes: an analysis of scope and claims.
    Paradise J; Andrews L; Holbrook T
    Science; 2005 Mar; 307(5715):1566-7. PubMed ID: 15761140
    [No Abstract]   [Full Text] [Related]  

  • 44. LabCorp v. Metabolite Laboratories: The Supreme Court listens, but declines to speak.
    Klein RD; Mahoney MJ
    J Law Med Ethics; 2008; 36(1):141-9, 4. PubMed ID: 18315767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Are natural gene sequences patentable?
    Becker KB
    Int Arch Occup Environ Health; 2000 Jun; 73 Suppl():S19-22. PubMed ID: 10968555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human genome 10th anniversary. The Human Genome (patent) Project.
    Kean S
    Science; 2011 Feb; 331(6017):530-1. PubMed ID: 21292952
    [No Abstract]   [Full Text] [Related]  

  • 47. Data disclosure crucial after DNA patent verdict.
    de Costa A
    Science; 2013 Aug; 341(6149):959. PubMed ID: 23990544
    [No Abstract]   [Full Text] [Related]  

  • 48. The fate and future of patents on human genes and genetic diagnostic methods.
    Huys I; Matthijs G; Van Overwalle G
    Nat Rev Genet; 2012 May; 13(6):441-8. PubMed ID: 22596320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Supreme Court ruling broadens BRCA testing options.
    Azvolinsky A
    J Natl Cancer Inst; 2013 Nov; 105(22):1671-2. PubMed ID: 24198329
    [No Abstract]   [Full Text] [Related]  

  • 50. Bridging the consumer-medical divide: how to regulate direct-to-consumer genetic testing.
    Edwards KT; Huang CJ
    Hastings Cent Rep; 2014; 44(3):17-9. PubMed ID: 24821248
    [No Abstract]   [Full Text] [Related]  

  • 51. [The Supreme Court free genes - economic and legal justifications - impacts on innovation and the healthcare offer].
    Cassier M; Stoppa-Lyonnet D
    Med Sci (Paris); 2015 Feb; 31(2):209-13. PubMed ID: 25744269
    [No Abstract]   [Full Text] [Related]  

  • 52. Property rights.
    Nature; 2009 Mar; 458(7237):385. PubMed ID: 19325578
    [No Abstract]   [Full Text] [Related]  

  • 53. Testing time for gene patents.
    Nature; 2010 Apr; 464(7291):957. PubMed ID: 20393513
    [No Abstract]   [Full Text] [Related]  

  • 54. French researchers take a stand against cancer gene patent.
    Butler D; Goodman S
    Nature; 2001 Sep; 413(6852):95-6. PubMed ID: 11557932
    [No Abstract]   [Full Text] [Related]  

  • 55. Do patents impede the provision of genetic tests in Australia?
    Nicol D; Liddicoat J
    Aust Health Rev; 2013 Jun; 37(3):281-5. PubMed ID: 23702081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. F.D.A. asks if a genetic test is sold without approval.
    Pollack A
    N Y Times Web; 2003 Jul; ():C2. PubMed ID: 14515843
    [No Abstract]   [Full Text] [Related]  

  • 57. Gene patenting--is the pendulum swinging back?
    Kesselheim AS; Mello MM
    N Engl J Med; 2010 May; 362(20):1855-8. PubMed ID: 20375396
    [No Abstract]   [Full Text] [Related]  

  • 58. Fetal tests spur legal battle.
    Hayden EC
    Nature; 2012 Jun; 486(7404):454. PubMed ID: 22739292
    [No Abstract]   [Full Text] [Related]  

  • 59. Preliminary CLIAC recommendations to regulate genetic testing.
    Press RD
    Mol Diagn; 2000 Sep; 5(3):245-7. PubMed ID: 11151838
    [No Abstract]   [Full Text] [Related]  

  • 60. Unlikely splicing: the Myriad decision, the Genomic Research and Accessibility Act, orphan diseases, and the future of antisense drugs.
    Ryan JL
    J Contemp Health Law Policy; 2011; 28(1):144-79. PubMed ID: 22292324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.